Rare Endocrine Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
170 Pages
January 2024
Region: Global
Fairfield Market Research
ID: 5925028

The global rare endocrine disease treatment market, intricately linked with obesity and endocrine disorders, is poised for moderate growth in the forecast period from 2024 to 2031, according to a recent research study conducted.

Endocrine Diseases and the Obesity Connection

Obesity, now considered a global pandemic, has been closely associated with a range of endocrine diseases, including both common conditions like polycystic ovarian syndrome and hypothyroidism, as well as rare ailments such as hypothalamic disorders and Cushing's syndrome.

The mechanisms underlying obesity development vary depending on the specific endocrine disorder. In the case of rare endocrine diseases, interactions with growth hormones and thyroid functions are pivotal, often coupled with increased adipogenesis and adipocyte differentiation.

Researchers Focus on Treatment Evaluation

Researchers worldwide are actively engaged in evaluating treatment strategies for rare endocrine diseases, with a particular emphasis on overweight patients. For instance, scientists at the University of Newcastle are diligently assessing the natural history of obesity development, taking into account the various etiological factors at play.

While a comprehensive evaluation has not yet been achieved, researchers are conducting laboratory tests and physical examinations to expand the evaluation process, ruling out common endocrine causes and paving the way for appropriate treatment selection.

Research Collaboration Revolutionizes Rare Endocrine Disease Treatment

The rarity of endocrine diseases poses challenges for researchers and clinicians in gathering sufficient patient data for robust clinical trials. The Endocrine Genomics Virtual Laboratory (endoVL) addresses this challenge by providing secure online access to analytical tools and extensive datasets, enabling collaborative efforts to advance the diagnosis and treatment of rare endocrine diseases.

With more than 8,500 registered cases of adrenal tumors, endoVL empowers researchers to leverage large cohorts for statistically significant analyses. Currently, more than 25 large-scale clinical trials are underway within endoVL, engaging research groups from around the world. This collaborative research effort holds immense potential to unlock new growth opportunities in the global rare endocrine disease treatment market.

Innovations in Ophthalmic Manifestations

Rare endocrine disorders often manifest multi-organ symptoms, initially appearing in the eyes through distinct pathophysiological disturbances. Recognizing ophthalmic manifestations of rare endocrine diseases is crucial for swift diagnosis, treatment, and the prevention of significant morbidity and mortality.

Biotechnology and pharmaceutical companies, alongside medical researchers, are expected to focus on addressing ophthalmic manifestations of rare endocrine diseases, fostering treatment developments and innovations in this critical area.

Key Players in Rare Endocrine Disease Treatment

Prominent companies contributing to advancements in rare endocrine disease treatment, as identified by PMR's report, include Novartis, Ipsen, Pfizer, Inc., Teva, EMD Serono, Novo Nordisk, Eli Lilly, Shire, Amgen, Inc., Corcept Therapeutics, and Novelion Therapeutics.

Notably, Spruce Biosciences, a clinical-stage biotechnology firm, recently received FDA orphan drug designation for its SPR001, a potential treatment for congenital adrenal hyperplasia (CAH), a rare endocrine disease.

Rare Endocrine Disease Treatment Market Segmentation

Indication

Acromegaly
Central Diabetes Insipidus
Ahumada-Del Castillo Syndrome
Hypoparathyroidism
Other Indications

Drug Type

Biologics
Organic Compounds

Mode of Administration

Injectables
Oral
Others

Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Region

North Americ
Latin America
Europe
Japan
APEJ
MEA

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Rare Endocrine Disease Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

3.1. Global Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Acromegaly
3.1.1.2. Central Diabetes Insipidus
3.1.1.3. Ahumada-Del Castillo Syndrome
3.1.1.4. Hypoparathyroidism
3.1.1.5. Other Indications
3.2. Global Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Biologics
3.2.1.2. Organic Compounds
3.3. Global Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Injectables
3.3.1.2. Oral
3.3.1.3. Others
3.4. Global Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. Hospital Pharmacies
3.4.1.2. Retail Pharmacies
3.4.1.3. Online Pharmacies
3.5. Global Rare Endocrine Disease Treatment Market Outlook, by Region, Value (US$ Mn) and Volume (Tons), 2018 - 2031
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa

4. North America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

4.1. North America Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Acromegaly
4.1.1.2. Central Diabetes Insipidus
4.1.1.3. Ahumada-Del Castillo Syndrome
4.1.1.4. Hypoparathyroidism
4.1.1.5. Other Indications
4.2. North America Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Biologics
4.2.1.2. Organic Compounds
4.3. North America Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Injectables
4.3.1.2. Oral
4.3.1.3. Others
4.4. North America Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. Hospital Pharmacies
4.4.1.2. Retail Pharmacies
4.4.1.3. Online Pharmacies
4.5. North America Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. U.S. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.5.1.2. U.S. Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.5.1.3. U.S. Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.5.1.4. U.S. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.5.1.5. Canada Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.5.1.6. Canada Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.5.1.7. Canada Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.5.1.8. Canada Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

5.1. Europe Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Acromegaly
5.1.1.2. Central Diabetes Insipidus
5.1.1.3. Ahumada-Del Castillo Syndrome
5.1.1.4. Hypoparathyroidism
5.1.1.5. Other Indications
5.2. Europe Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Biologics
5.2.1.2. Organic Compounds
5.3. Europe Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Injectables
5.3.1.2. Oral
5.3.1.3. Others
5.4. Europe Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Hospital Pharmacies
5.4.1.2. Retail Pharmacies
5.4.1.3. Online Pharmacies
5.5. Europe Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. Germany Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.2. Germany Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.3. Germany Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.4. Germany Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.5. U.K. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.6. U.K. Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.7. U.K. Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.8. U.K. Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.9. France Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.10. France Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.11. France Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.12. France Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.13. Italy Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.14. Italy Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.15. Italy Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.16. Italy Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.17. Turkey Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.18. Turkey Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.19. Turkey Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.20. Turkey Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.21. Russia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.22. Russia Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.23. Russia Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.24. Russia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.25. Rest of Europe Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.26. Rest of Europe Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.27. Rest of Europe Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.1.28. Rest of Europe Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

6.1. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Acromegaly
6.1.1.2. Central Diabetes Insipidus
6.1.1.3. Ahumada-Del Castillo Syndrome
6.1.1.4. Hypoparathyroidism
6.1.1.5. Other Indications
6.2. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Biologics
6.2.1.2. Organic Compounds
6.3. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Injectables
6.3.1.2. Oral
6.3.1.3. Others
6.4. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Hospital Pharmacies
6.4.1.2. Retail Pharmacies
6.4.1.3. Online Pharmacies
6.5. Asia Pacific Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. China Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.2. China Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.3. China Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.4. China Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.5. Japan Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.6. Japan Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.7. Japan Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.8. Japan Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.9. South Korea Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.10. South Korea Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.11. South Korea Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.12. South Korea Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.13. India Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.14. India Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.15. India Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.16. India Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.17. Southeast Asia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.18. Southeast Asia Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.19. Southeast Asia Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.20. Southeast Asia Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.21. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.22. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.23. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.1.24. Rest of Asia Pacific Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

7.1. Latin America Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Acromegaly
7.1.1.2. Central Diabetes Insipidus
7.1.1.3. Ahumada-Del Castillo Syndrome
7.1.1.4. Hypoparathyroidism
7.1.1.5. Other Indications
7.2. Latin America Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Biologics
7.2.1.2. Organic Compounds
7.3. Latin America Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Injectables
7.3.1.2. Oral
7.3.1.3. Others
7.4. Latin America Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Hospital Pharmacies
7.4.1.2. Retail Pharmacies
7.4.1.3. Online Pharmacies
7.5. Latin America Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Brazil Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.2. Brazil Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.3. Brazil Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.4. Brazil Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.5. Mexico Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.6. Mexico Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.7. Mexico Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.8. Mexico Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.9. Argentina Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.10. Argentina Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.11. Argentina Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.12. Argentina Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.13. Rest of Latin America Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.14. Rest of Latin America Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.15. Rest of Latin America Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.1.16. Rest of Latin America Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, 2018 - 2031

8.1. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Acromegaly
8.1.1.2. Central Diabetes Insipidus
8.1.1.3. Ahumada-Del Castillo Syndrome
8.1.1.4. Hypoparathyroidism
8.1.1.5. Other Indications
8.2. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Biologics
8.2.1.2. Organic Compounds
8.3. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Injectables
8.3.1.2. Oral
8.3.1.3. Others
8.4. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Hospital Pharmacies
8.4.1.2. Retail Pharmacies
8.4.1.3. Online Pharmacies
8.5. Middle East & Africa Rare Endocrine Disease Treatment Market Outlook, by Country, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. GCC Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.2. GCC Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.3. GCC Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.4. GCC Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.5. South Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.6. South Africa Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.7. South Africa Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.8. South Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.9. Egypt Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.10. Egypt Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.11. Egypt Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.12. Egypt Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.13. Nigeria Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.14. Nigeria Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.15. Nigeria Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.16. Nigeria Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.17. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Distribution Channel, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.18. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Drug Type, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.19. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Mode of Administration, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.1.20. Rest of Middle East & Africa Rare Endocrine Disease Treatment Market by Indication, Value (US$ Mn) and Volume (Tons), 2018 - 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. by Mode of Administration vs by Drug Type Heatmap
9.2. Manufacturer vs by Drug Type Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Novartis
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Ipsen
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Pfizer, Inc
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Teva
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. EMD serono
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Novo Nordisk
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Eli Lilly
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Shire
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Amgen, Inc
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Corcept Therapeutics
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Novelion Therapeutics
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12.

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

Novartis
Ipsen
Pfizer, Inc.
Teva
EMD serono
Novo Nordisk
Eli Lilly
Shire
Amgen, Inc.
Corcept Therapeutics
Novelion Therapeutics

Methodology

LOADING...

Endocrine Diseases and the Obesity Connection

Researchers Focus on Treatment Evaluation

Research Collaboration Revolutionizes Rare Endocrine Disease Treatment

Innovations in Ophthalmic Manifestations

Key Players in Rare Endocrine Disease Treatment

Rare Endocrine Disease Treatment Market Segmentation

Table of Contents

Companies Mentioned

Methodology

Related Topics

Related Reports

Rare Endocrine Disease Treatment - Global Strategic Business Report

Somatostatin Analogs Market by Type, Application - Global Forecast 2025-2030

Acromegaly Global Market Report 2024

Endocrinology Drugs Market by Therapy Area, Distribution Channel - Global Forecast 2025-2030

Cushings Syndrome and Acromegaly Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)